J. Mamza

First name
J.
Middle name
B.
Last name
Mamza
Mizani, M. A., Dashtban, A. ., Pasea, L. ., Zeng, Q. ., Khunti, K. ., Valabhji, J. ., … Banerjee, A. . (2024). Identifying subtypes of type 2 diabetes mellitus with machine learning: development, internal validation, prognostic validation and medication burden in linked electronic health records in 420 448 individuals. BMJ Open Diabetes Res Care, 12. http://doi.org/10.1136/bmjdrc-2024-004191
Dashtban, A. ., Mizani, M. A., Pasea, L. ., Denaxas, S. ., Corbett, R. ., Mamza, J. B., … Banerjee, A. . (2023). Identifying subtypes of chronic kidney disease with machine learning: development, internal validation and prognostic validation using linked electronic health records in 350,067 individuals. EBioMedicine, 89, 104489. http://doi.org/10.1016/j.ebiom.2023.104489
Mizani, M. A., Dashtban, A. ., Pasea, L. ., Lai, A. G., Thygesen, J. ., Tomlinson, C. ., … Banerjee, A. . (2022). Using national electronic health records for pandemic preparedness: validation of a parsimonious model for predicting excess deaths among those with COVID-19-a data-driven retrospective cohort study. J R Soc Med, 1410768221131897. http://doi.org/10.1177/01410768221131897
Idris, I. ., Zhang, R. ., Mamza, J. B., Ford, M. ., Morris, T. ., Banerjee, A. ., & Khunti, K. . (2021). Lower risk of hospitalization for heart failure, kidney disease and death with sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in type 2 diabetes regardless of prior cardiovascular or kidney disease. Diabetes Obes Metab, 23, 2207–2214. http://doi.org/10.1111/dom.14437
Birkeland, K. I., Bodegard, J. ., Banerjee, A. ., Kim, D. J., Norhammar, A. ., Eriksson, J. W., … Kadowaki, T. . (2021). Lower cardiorenal risk with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study. Diabetes Obes Metab, 23, 75–85. http://doi.org/10.1111/dom.14189
Idris, I. ., Zhang, R. ., Mamza, J. B., Ford, M. ., Morris, T. ., Banerjee, A. ., & Khunti, K. . (2022). Significant reduction in chronic kidney disease progression with sodium-glucose cotransporter-2 inhibitors compared to dipeptidyl peptidase-4 inhibitors in adults with type 2 diabetes in a UK clinical setting. Diabetes Obes Metab. http://doi.org/10.1111/dom.14799
Dashtban, A. ., Mizani, M. A., Denaxas, S. ., Nitsch, D. ., Quint, J. ., Corbett, R. ., … Banerjee, A. . (2022). A retrospective cohort study measured predicting and validating the impact of the COVID-19 pandemic in individuals with chronic kidney disease. Kidney Int. http://doi.org/10.1016/j.kint.2022.05.015
Gurol-Urganci, I. ., Geary, R. S., Mamza, J. B., Iwagami, M. ., El-Hamamsy, D. ., Duckett, J. ., … van der Meulen, J. . (2020). Determinants of referral of women with urinary incontinence to specialist services: a national cohort study using primary care data from the UK. BMC Fam Pract. http://doi.org/10.1186/s12875-020-01282-y